Active ingredientGolidocitinibCat. No. P-G054-001CAS 2091134-68-6Family · Pharmaceutical analytical standards
Golidocitinib
An oral selective JAK1 inhibitor, approved in China in June 2024 for relapsed or refractory peripheral T-cell lymphoma after at least one previous therapy. This family brings together the active ingredient.
Did you know?In the laboratory it is 200 to 400 times more selective for JAK1 than for the other Janus kinases; in the United States it had already received Fast Track designation in 2022.
Go to the active ingredient →Active ingredientGolidocitinibCat. No. P-G054-001CAS 2091134-68-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.